Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
about
Natalizumab for relapsing remitting multiple sclerosisGLANCE: results of a phase 2, randomized, double-blind, placebo-controlled studyNatalizumab: A new treatment for relapsing remitting multiple sclerosisLeukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory diseaseBenefits versus risks of latest therapies in multiple sclerosis: a perspective reviewNatalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosisProgressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.Extended interval dosing of natalizumab in multiple sclerosis.Gene variants of adhesion molecules act as modifiers of disease severity in MS.Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.Natalizumab in the treatment of multiple sclerosisEfficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 studyNatalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.Interferon-beta1b for multiple sclerosis.Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.Challenges and opportunities: what we are learning from the clinical natalizumab experience.Natalizumab for the treatment of multiple sclerosis and Crohn's disease.Natalizumab and progressive multifocal leucoencephalopathy.Clinical effects of natalizumab on multiple sclerosis appear early in treatment courseMonoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases.Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy.Treating multiple sclerosis with monoclonal antibodies.Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.Current and future therapies for multiple sclerosis.Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient.Clinical evaluation of natalizumab for formulary consideration.Natalizumab (Tysabri).Fingolimod for the treatment of relapsing multiple sclerosis.Managing MS in a changing treatment landscape.Treating multiple sclerosis with natalizumab.Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.Monoclonal antibodies based on hybridoma technology.Established and novel disease-modifying treatments in multiple sclerosis.
P2860
Q24235861-1C14139B-E2B8-47E5-9108-F7116CAFA258Q24647794-90BA4142-31E7-4C9C-807F-B318C02DFDE5Q24683014-8CD1972E-9CC0-4902-BF76-E9C3A75A962AQ26822941-FD20431A-AB96-43D1-9DC9-5F487C2D951FQ26999417-A4ACAD1E-480D-4F92-A4B2-BEEE95309624Q28277470-BBC33DA4-687E-4CA6-91F6-50E53219ACF5Q30354301-51402830-A562-4C88-BDE3-3AC5FB0D0F3CQ30354658-4662015E-5345-4FB2-9841-FFD8729B1FB2Q31049360-B425C37D-1A2C-485F-BECB-87BA5DA1F7D8Q33605178-DF3493D1-7591-48E6-8AD2-F6A2D2E410CCQ33678267-00422E8E-95F0-4978-826C-27466AA206DEQ34409340-713753C3-9065-4943-9935-C8500F70B00DQ34431300-A5C69714-574F-4A3E-8A85-FF8390918682Q34614995-DA9D905C-E251-4B98-8316-DA9A9E0AD2D6Q35194642-4884BA1B-BC7D-4649-9B85-0E4B623C24DDQ35276622-BD7F90D5-5345-4A82-873A-081E9E5FDA1CQ35895287-4E2D2978-AB37-44CC-83FC-CD87CF650A7DQ35939675-A51DE864-A54C-4037-B322-F4EDF3186965Q36073992-37DCE460-D9CD-4DD0-83AE-31880E87712CQ36106790-04207F38-B7A6-46D5-BF17-097AAF6FCB6BQ36223650-CF25010A-BA44-4269-B4D5-EC1F3AEA5E75Q36257198-4B95EAC4-3ED1-4C01-A63C-EE730EC6DB1AQ36284072-32771083-DEBB-4EDB-8482-43028132463DQ36622383-D53105F5-F3A6-4004-9DF7-0452F6273315Q36812543-68774468-3396-4C94-A667-B3478BC52483Q36922576-C15D9226-740F-426D-B47C-B54D2CC476D1Q37009992-C70728CD-07FF-4670-B3B4-C45535066CFEQ37111904-0E0ACEEB-B550-4DEB-9708-65A51534E43EQ37180600-DC98F7D4-DF76-4713-BD00-96CAF569501FQ37287769-080061C4-A303-4458-82EF-23AF2D33A556Q37653126-C442CDEC-B154-4BBD-ADFA-440FAFAEF144Q37772171-518F251A-9171-4EAE-A677-C0B39AC5B0C3Q37778197-A98B0554-B27A-48CA-B839-9F753912F104Q37821010-3234521C-1947-480D-AF36-898855FBF095Q37857752-4C80490E-3FD7-4185-BE6A-29A49BF7B393Q37957123-EF6F433B-E7A2-4C14-8E68-D4F4E21573F7Q37968620-1CC0F5F6-456D-4A3D-845B-0C1A153D081CQ37982013-B5792AE3-E52E-4911-8749-0B617A41DD2BQ38162972-1CDE8E41-5121-4143-BD18-27E57D2BABBBQ38180157-7A9D6D36-43FC-4BAD-8463-CAE6A258AB3B
P2860
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
@ast
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
@en
type
label
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
@ast
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
@en
prefLabel
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
@ast
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
@en
P356
P1476
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
@en
P2093
Alfred Sandrock
Richard A Rudick
P2860
P304
P356
10.1586/14737175.4.4.571
P577
2004-07-01T00:00:00Z